Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.
Dermatology Times Staff
Advertisement
Articles by Dermatology Times Staff
Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.
Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Topical retapamulin was effective in clearing impetigo lesions according to a presentation given at the recent Maui Derm conference.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
MJH Life Sciences COVID-19 Coalition webinar on Jan. 26 will focus on COVID-19 variants emerging around the globe.
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
